PHAR, in collaboration with Novartis, published findings from a modified Delphi panel summarizing expert clinical consensus on managing infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) who are treated with crizanlizumab. IRR management in patients with SCD is dependent on key patient characteristics including: prior history of IRRs to other monoclonal antibodies or medications, changes to crizanlizumab infusion rate and patient monitoring, pain severity relative to patient’s typical SCD crises, and severe allergic symptoms. The full manuscript detailing the methods and findings are published in Annals of Hematology, or can be found on the PHAR publications page.